A T -
cell marker panel that can identify subsets of tumor - associated T - cells allows scientists to identify and target subpopulations of T - cells playing unique roles in the immune response against a tumor.
Not exact matches
Two additional
panels will be established allowing more than 60 different immune
markers to be monitored at the single -
cell level, followed by data analysis using SB tools available at CEA.
We also interrogated the population of sorted, CD81 - negative
cells for the expression of pluripotency
markers (Figure 4,
Panel B) and identified that successfully edited hiPS
cells were 92.6 % Oct ‑ 4 positive, 99.7 % TRA ‑ 1 ‑ 60 positive, and 99.99 % SSEA - 4 positive.
Panel B. CD81 - negative
cells were examined for pluripotency
markers Oct ‑ 4, TRA ‑ 1 ‑ 60, and SSEA - 4.
RT - PCR analysis of RNA samples from EBs on days 3, 6 and 9 revealed a gradual decrease in expression of endogenous pluripotency
markers such as Nanog, Rex1, Oct4 and Sox2 as compared to their expression in undifferentiated iPS
cells (Figure 4B, upper
panel).
We also found expression of a wide
panel of
markers expressed in hESCs in our iPS
cells, which include OCT3 / 4, SSEA - 3, TRA -1-60, TRA -1-81, NANOG, KLF4, and LIN28 (Figure 2E — M).
(E) Western blot analysis of iPS - RPE protein expression using antibodies against a
panel of RPE
cell markers.
The cytotoxicities of IMGN632 and X-ADC were first assessed in a
panel of AML
cell lines, which expressed CD123 at levels similar to AML blast
cells (ABC values, 1100 - 13000) and encompassed a variety of poor prognostic
markers (Table 1).